ストックスクリーナーアプリを入手
66.37
1.66%
-1.12
前日終値:
$67.49
開ける：
$67.94
24時間の取引高:
558.36K
Relative Volume:
0.79
時価総額：
$1.68B
収益：
$302.00K
当期純損益:
$-117.10M
株価収益率:
-5.9632
EPS:
-11.13
ネットキャッシュフロー:
$-129.13M
1週間 パフォーマンス:
+1.77%
1か月 パフォーマンス:
+7.87%
6か月 パフォーマンス:
+208.12%
1年 パフォーマンス:
+410.54%
1日の値動き範囲:
$65.69
$68.00
1週間の範囲:
$59.80
$69.36
52週間の値動き範囲:
$10.14
$69.36
Cidara Therapeutics Inc Stock (CDTX) Company Profile
名前
Cidara Therapeutics Inc
セクター
電話
858-752-6170
住所
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
CDTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
66.37 | 1.60B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-03-12 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-01-27 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-11-08 | 開始されました | Guggenheim | Buy |
| 2024-08-14 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | 再開されました | H.C. Wainwright | Buy |
| 2021-09-22 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | 開始されました | Aegis Capital | Buy |
| 2019-09-04 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-07-26 | 開始されました | Citigroup | Buy |
| 2017-04-21 | 開始されました | Raymond James | Strong Buy |
| 2017-04-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-04-11 | 再開されました | Wedbush | Outperform |
| 2017-02-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-22 | アップグレード | WBB Securities | Sell → Hold |
| 2016-12-21 | 再開されました | Leerink Partners | Outperform |
| 2016-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2016-09-23 | ダウングレード | WBB Securities | Hold → Sell |
| 2015-10-09 | アップグレード | WBB Securities | Sell → Hold |
| 2015-05-11 | 開始されました | Jefferies | Buy |
| 2015-05-11 | 開始されました | Leerink Partners | Outperform |
| 2015-05-11 | 開始されました | Needham | Buy |
| 2015-05-11 | 開始されました | Wedbush | Outperform |
| 2015-04-23 | 開始されました | WBB Securities | Sell |
すべてを表示
Cidara Therapeutics Inc (CDTX) 最新ニュース
Cidara Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Pullbacks & Momentum Based Trading Ideas - beatles.ru
Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN
Will Cidara Therapeutics Inc. bounce back from current supportGold Moves & Capital Efficiency Focused Strategies - Newser
Comparing Cidara Therapeutics Inc. in custom built stock radarsPrice Action & Daily Stock Momentum Reports - Newser
What Fibonacci levels say about Cidara Therapeutics Inc. rebound2025 Volatility Report & Fast Entry and Exit Trade Plans - Newser
Is Cidara Therapeutics Inc. a candidate for recovery playAnalyst Downgrade & High Conviction Buy Zone Alerts - Newser
What MACD and RSI say about Cidara Therapeutics Inc.2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
What does recent volatility data suggest for Cidara Therapeutics Inc.Index Update & Fast Momentum Entry Tips - Newser
Is Cidara Therapeutics Inc. trending in predictive chart models2025 Bull vs Bear & Short-Term Trading Alerts - Newser
Comparing LakeShore Biopharma (NASDAQ:LSB) and Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionQuarterly Market Review & Stepwise Trade Execution Plans - Newser
Published on: 2025-08-15 18:00:40 - Newser
Cidara Therapeutics Inc. stock trend outlook and recovery path2025 Technical Overview & Fast Momentum Stock Entry Tips - Newser
Cidara Therapeutics: A High-Conviction Biotech Play with Clear Path to FDA Phase 3 and Market Disruption - AInvest
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX) - Seeking Alpha
Fund Update: MORGAN STANLEY added 875,198 shares of CIDARA THERAPEUTICS (CDTX) to their portfolio - Quiver Quantitative
Analyzing recovery setups for Cidara Therapeutics Inc. investorsEarnings Overview Summary & AI Powered Buy/Sell Recommendations - Newser
Published on: 2025-08-15 04:34:11 - Newser
Will Cidara Therapeutics Inc. stock split in the near future2025 Performance Recap & Risk Managed Trade Strategies - Newser
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN
What recovery options are there for Cidara Therapeutics Inc.July 2025 Short Interest & Low Risk High Reward Ideas - Newser
Cidara (CDTX) Q2 Cash Surges 163% - AOL.com
Cidara Therapeutics Inc. Pullback Analyzed — Is It Time to ExitMarket Entry and Exit Point Tips From Traders - beatles.ru
JMP Securities Raises Cidara Therapeutics (NASDAQ:CDTX) Price Target to $66.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at Needham & Company LLC - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 - Defense World
A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛
Cidara Therapeutics 2024 Q2 Earnings Net Loss Widens by 569.5% - AInvest
What moving averages say about Cidara Therapeutics Inc.Free Smart Trade Plans With Risk Protection - Newser
Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks
Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada
Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize
Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks
Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com
Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate
Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... By GuruFocus - Investing.com Canada
Cidara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cidara Therapeutics 2024 Q2 Earnings Deepened Losses Amid Strong Clinical Progress - AInvest
Transcript : Cidara Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82) - TipRanks
Cidara Therapeutics Q2 net loss narrows - MarketScreener
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
Cidara Therapeutics Inc (CDTX) 財務データ
収益
当期純利益
現金流量
EPS
Cidara Therapeutics Inc (CDTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
| Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):